CAMBRIDGE, Mass. and EXTON, Pa., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 22nd Annual NewsMakers in the Biotech Industry Conference on Thursday, September 10, 2015 at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York City.
Live audio webcasts of Idera's presentations will be accessible in the Investors and Media section of Idera's website at http://www.iderapharma.com. Archived versions will also be available on the Company's website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera's proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera is developing a third generation antisense technology platform that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
CONTACT: Investor and Media Contact
Robert Doody
VP, IR & Corporate Communications
617-679-5515 (office)
484-639-7235 (mobile)
rdoody@iderapharma.com
Idera Pharmaceuticals
